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Epidemiology of hepatocellular carcinoma (HCC) is changing globally and trends show an increasing 
morbidity rates in Northern, Cen tral and Eastern Europe and North America but a slow decline in Japan, Ko-
rea and China. The bur den of this important complication of chronic advanced liver disease will further in-
crease in the next 10 years. Several reviews focus on a broad spectrum of HCC clinical manage ment world-
wide, including surveillance of patients with cirrhosis thus establishing proper HCC diagnostic and therapeu-
tic options. 
The study of I. Ivanova et al. involves patient data from a single referral center in St. Marina University 
Hospital of Varna. It is the first report of the results of a project enti tled ‘Hepatocellular Carcinoma - a Cur-
rent Diagnos tic and Therapeutic Approach’. The study achieves its goal to present the results from this multi-
disciplinary HCC treatment. 
This is one of the three largest cohort studies in Bulgaria so far. The paper reports 240 HCC patients dur-
ing an 11-year period (from 2006 to 2016) in the Clinic of Gastroenterology, St. Marina University Hospital of 
Varna. These results aim at evaluating the risk factors for HCC and etiology of chron ic liver disease, the char-
acteristics and severity of underlying liver disease, the methods for HCC diagnosis and tumor burden as well 
as staging and treatment methods. 
The analysis of the risk factors for HCC and etiology of chron ic liver disease shows that chronic hepati-
tis-B virus (HBV) infection has been registered in 40.4% and chronic hepatitis-C virus (HCV) infection - in 
25.8% of HCC patients. There are two cases with HBV/HCV co-infection and four had HBV/hepatitis-D vi-
rus (HDV) co-infection. The other rare etiologic factors for chronic liver disease in our cohort are the follow-
ing: Wilson’s disease in three, autoimmune hepatitis - in two and non-alco holic fatty liver disease (NAFLD) - 
in one patient. Unknown etiology has been registered in 28 patients, as 10 of them (36%) have presented with 
a marker for exposure to HBV (anti-HBc positive antibodies). Despite the common understanding of the link 
between liver cirrhosis and HCC, only 82% of HCC patients have developed this pathology. HCC is the first 
complication of chronic liver dis ease in 2/3 of cases (n=156). One limitation of the study when comparing lab-
oratory results is the lack of similar cohort of patients without malignant transformation. 
The diagnostic algorithm includes various imaging and biopsy modalities. The primary diagnosis of 
HCC is based on at least two imaging methods in 133 cases. In any other patients, the imaging method is com-
bined with at least one ultasonography- or computed-tomography-guided biopsy of the he patic lesions. The 
pa tients with very early and early HCC stage account for 13% of all HCCs. 
The treatment modalities encompass every current modality available such as surgical resection (in 23%), 
radiofrequency ablation (in 5%) and transarterial chemoembolization (TACE) (in 2% of the cases). System ic 
therapy, predominantly with Sorafenib, has been intro duced to 17% of the patients.
The significance of ultrasound surveillance in liver cirrhosis patients is confirmed with the large percent-
age of diagnosed tumors - 51%. In contrast, most HCCs are detected at stage D, mainly due to advance base-
line liver cirrhosis.
In summary, findings from this study confirm that surveillance with ultrasound and tumor markers 
like alpha-fetoprotein (AFP) among pa tients with advanced liver disease may increase HCC detection rate and 
achieve longer patient survival rate. 
